LPAR2-mediated action promotes human renal cell carcinoma via MAPK/NF-κB signaling to regulate cytokine network

[1]  Zhi-Jian Han,et al.  Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy , 2021, Molecules.

[2]  A. Damirin,et al.  LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer , 2021, Medical Oncology.

[3]  K. Meier,et al.  Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special? , 2021, Cells.

[4]  Jing Liu,et al.  Mechanism of Anti-Inflammatory and Antibacterial Effects of QingXiaoWuWei Decoction Based on Network Pharmacology, Molecular Docking and In Vitro Experiments , 2021, Frontiers in Pharmacology.

[5]  B. Mathew,et al.  Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development. , 2021, European journal of medicinal chemistry.

[6]  D. Brindley.  Lysophosphatidic Acid Signaling in Cancer , 2020, Cancers.

[7]  P. Russo,et al.  The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. , 2020, European urology.

[8]  X. Fang,et al.  Lysophosphatidic acid induces tumor necrosis factor‐alpha to regulate a pro‐inflammatory cytokine network in ovarian cancer , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  T. Tsujiuchi,et al.  Different effects of lysophosphatidic acid receptor-2 (LPA2) and LPA5 on the regulation of chemoresistance in colon cancer cells , 2020, Journal of receptor and signal transduction research.

[10]  A. Avan,et al.  Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer. , 2020, Gene.

[11]  A. Damirin,et al.  LPA receptor1 antagonists as anticancer agents suppress human lung tumours. , 2019, European journal of pharmacology.

[12]  F. Zhou,et al.  Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors , 2019, American journal of clinical oncology.

[13]  Xiao Zhang,et al.  Lysophosphatidic acid induces the migration and invasion of SGC-7901 gastric cancer cells through the LPA2 and Notch signaling pathways , 2019, International journal of molecular medicine.

[14]  T. A. Al Hussain,et al.  Papillary Renal Cell Carcinoma (PRCC): An Update. , 2019, Advances in anatomic pathology.

[15]  L. Johnson,et al.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential , 2019, Journal of Lipid Research.

[16]  R. Harris,et al.  Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model. , 2017, Journal of the American Society of Nephrology : JASN.

[17]  O. Sokolova,et al.  NF-κB Signaling in Gastric Cancer , 2017, Toxins.

[18]  D. Xiao,et al.  Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1α expression and breast cancer cell growth. , 2016, Oncology reports.

[19]  K. Hasegawa,et al.  Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels , 2016, PloS one.

[20]  A. Bhatt,et al.  Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.

[21]  N. Perkins,et al.  NFKB1: a suppressor of inflammation, ageing and cancer , 2016, The FEBS journal.

[22]  Duane D. Miller,et al.  Novel Inhibitory Effect of a Lysophosphatidic Acid 2 Agonist on Allergen-Driven Airway Inflammation. , 2016, American journal of respiratory cell and molecular biology.

[23]  Y. Okada,et al.  Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer , 2016, Nature Communications.

[24]  Huanjie Shao,et al.  Lysophosphatidic Acid Up-Regulates Hexokinase II and Glycolysis to Promote Proliferation of Ovarian Cancer Cells1 , 2015, Neoplasia.

[25]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[26]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[27]  Dezhi Yang,et al.  Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2 , 2013, Oncology letters.

[28]  Julie Klein,et al.  Lysophosphatidic acid-1-receptor targeting agents for fibrosis , 2011, Expert opinion on investigational drugs.

[29]  Guoxin Zhang,et al.  Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells , 2011, BMC Cell Biology.

[30]  Akira Shiraishi,et al.  Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. , 2008, Biochemical and biophysical research communications.

[31]  M. Deng,et al.  Tumor‐derived tumor necrosis factor‐alpha promotes progression and epithelial‐mesenchymal transition in renal cell carcinoma cells , 2008, Cancer science.

[32]  A. Shiraishi,et al.  The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. , 2007, Biochemical and biophysical research communications.

[33]  G. Mills,et al.  Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer , 2006, Clinical Cancer Research.

[34]  B. Olde,et al.  Lysophosphatidic Acid Binds to and Activates GPR92, a G Protein-Coupled Receptor Highly Expressed in Gastrointestinal Lymphocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[35]  G. Mills,et al.  Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .

[36]  Hyunsuk Shim,et al.  LPA2 receptor mediates mitogenic signals in human colon cancer cells. , 2005, American journal of physiology. Cell physiology.

[37]  G. Mills,et al.  Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.

[38]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[39]  Takao Shimizu,et al.  Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family* , 2003, Journal of Biological Chemistry.

[40]  W. Moolenaar.  Bioactive lysophospholipids and their G protein-coupled receptors. , 1999, Experimental cell research.

[41]  Hiroyuki Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid* , 1999, The Journal of Biological Chemistry.

[42]  E. Goetzl,et al.  Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid* , 1998, The Journal of Biological Chemistry.

[43]  J. Weiner,et al.  Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex , 1996, The Journal of cell biology.

[44]  ボクラベック ポトツカ イザベラ,et al.  妊娠初期における Lysophosphatidic acid の生理的役割 , 2009 .

[45]  G. Mills,et al.  Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. , 2006, Cancer research.

[46]  H. Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor , EDG 7 , for Lysophosphatidic Acid * , 1999 .